Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers

Active:	No
Cancer Type:	Lymphoma	NCT ID:	NCT03005782
Trial Phases:	Phase I	Protocol IDs:	R3767-ONC-1613 (primary) NCI-2017-00409 2016-002789-30
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Regeneron Pharmaceuticals, Inc.
NCI Full Details:	http://clinicaltrials.gov/show/NCT03005782

Summary

The primary objectives in the dose escalation phase are to evaluate safety and
pharmacokinetics (PK) in order to determine the selected dose level(s) for expansion of
REGN3767 as monotherapy and in combination with cemiplimab in patients with advanced
malignancies, including lymphoma.

The primary objectives in the dose expansion phase are to assess preliminary anti-tumor
activity of REGN3767 alone and in combination with cemiplimab (separately by cohort) as
measured by objective response rate (ORR).

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
404-778-5180
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.